10 P’s

10P Therapeutics is a biotechnology company dedicated to developing first-in-class treatments for 10p deletion syndrome, a rare genetic disorder characterized by a spectrum of clinical features including hypoparathyroidism, sensorineural deafness, and renal disease (HDR syndrome). The company focuses on addressing the haploinsufficiency of the GATA3 transcription factor, which is the primary driver of the condition's pathology. By leveraging insights into the molecular mechanisms of GATA3 regulation, 10P Therapeutics aims to restore functional protein levels to alleviate the multi-organ complications associated with the syndrome. Their pipeline includes small molecule and potentially genetic approaches designed to modify the course of this underserved orphan disease. The company is currently in the pre-clinical stage, advancing its lead programs toward regulatory filings.